{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:57:35Z","timestamp":1791284255819,"version":"4.1.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.4065\/mcp.2011.0203","type":"journal-article","created":{"date-parts":[[2011,5,31]],"date-time":"2011-05-31T18:03:12Z","timestamp":1306864992000},"page":"561-583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["Antiparasitic Therapy"],"prefix":"10.4065","volume":"86","author":[{"given":"Shanthi","family":"Kappagoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4065\/mcp.2011.0203_bib1","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.4065\/mcp.2011.0203_bib2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4269\/ajtmh.2009.80.126","article-title":"Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria?","volume":"80","author":"Maude","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(05)67176-0","article-title":"Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial","volume":"366","author":"Dondorp","year":"2005","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0203_bib4","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(10)61924-1","article-title":"Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial","volume":"376","author":"Dondorp","year":"2010","journal-title":"Lancet"},{"issue":"30","key":"10.4065\/mcp.2011.0203_bib5","first-page":"769","article-title":"Notice to readers: new medication for severe malaria available under an investigational new drug protocol","volume":"56","author":"Centers for Disease Control and Prevention (CDC)","year":"2007","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.4065\/mcp.2011.0203_bib6","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1086\/657402","article-title":"Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria","volume":"51","author":"Bethell","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/1475-2875-9-238","article-title":"Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections","volume":"9","author":"Daneshvar","year":"2010","journal-title":"Malar J"},{"key":"10.4065\/mcp.2011.0203_bib8","series-title":"Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000-2010","author":"World Health Organization (WHO)","year":"2010"},{"key":"10.4065\/mcp.2011.0203_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0203_bib11","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1086\/655831","article-title":"Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial","volume":"51","author":"Valecha","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib12","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(10)60322-4","article-title":"Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial","volume":"375","author":"Tshefu","year":"2010","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0203_bib13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1086\/653710","article-title":"Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial","volume":"202","author":"Thriemer","year":"2010","journal-title":"J Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","article-title":"Human African trypanosomiasis","volume":"375","author":"Brun","year":"2010","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0203_bib15","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0140-6736(89)92340-4","article-title":"Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness","volume":"1","author":"Pepin","year":"1989","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0203_bib16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0203_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1086\/510534","article-title":"Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness","volume":"195","author":"Bisser","year":"2007","journal-title":"J Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib18","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1371\/journal.pctr.0010039","article-title":"Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda","volume":"1","author":"Priotto","year":"2006","journal-title":"PLoS Clin Trials"},{"key":"10.4065\/mcp.2011.0203_bib19","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1046\/j.1365-3156.2001.00775.x","article-title":"The phenomenon of treatment failures in Human African Trypanosomiasis","volume":"6","author":"Brun","year":"2001","journal-title":"Trop Med Int Health"},{"key":"10.4065\/mcp.2011.0203_bib20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/bmj.39485.592674.BE","article-title":"Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study","volume":"336","author":"Priotto","year":"2008","journal-title":"BMJ"},{"key":"10.4065\/mcp.2011.0203_bib21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-3156.2005.01545.x","article-title":"Drug-resistance of Trypanosoma b. rhodesiense isolates from Tanzania","volume":"11","author":"Kibona","year":"2006","journal-title":"Trop Med Int Health"},{"key":"10.4065\/mcp.2011.0203_bib22","unstructured":"Torreele E. Fexinidazole: a rediscovered nitroimidazole drug candidate moving into clinical development for HAT. Presented at 57th ASTMH Annual Meeting. New Orleans, LA: December 7-11, 2008."},{"key":"10.4065\/mcp.2011.0203_bib23","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.298.18.2171","article-title":"Evaluation and treatment of Chagas disease in the United States: a systematic review","volume":"298","author":"Bern","year":"2007","journal-title":"JAMA"},{"key":"10.4065\/mcp.2011.0203_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4269\/ajtmh.2000.63.111","article-title":"Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives","volume":"63","author":"Lauria-Pires","year":"2000","journal-title":"Am J Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.actatropica.2009.10.023","article-title":"Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches","volume":"115","author":"Urbina","year":"2010","journal-title":"Acta Trop"},{"key":"10.4065\/mcp.2011.0203_bib26","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(96)04128-1","article-title":"Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection","volume":"348","author":"de Andrade","year":"1996","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0203_bib27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4269\/ajtmh.1998.59.526","article-title":"Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease","volume":"59","author":"Sosa Estani","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.7326\/0003-4819-144-10-200605160-00006","article-title":"Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a non-randomized trial","volume":"144","author":"Viotti","year":"2006","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"10.4065\/mcp.2011.0203_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1590\/S0074-02762009000900042","article-title":"The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease","volume":"104","author":"Marin-Neto","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.4065\/mcp.2011.0203_bib30","unstructured":"National Institutes of Health, National Library of Medicine, US Department of Health and Human Services. Clinical trial for the treatment of chronic Chagas disease with posaconazole and benznidazole (CHAGASAZOL). ClinicalTrials.Gov Web site. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01162967. Accessed April 29, 2011."},{"key":"10.4065\/mcp.2011.0203_bib31","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0203_bib32","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0203_bib33","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(05)67629-5","article-title":"Advances in leishmaniasis","volume":"366","author":"Murray","year":"2005","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0203_bib34","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/318121","article-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib35","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0203_bib36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1473-3099(10)70011-6","article-title":"Combination therapy for visceral leishmaniasis","volume":"10","author":"van Griensven","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4269\/ajtmh.2007.77.89","article-title":"Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy","volume":"77","author":"Melaku","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multi-drug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0203_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004834.pub2","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis","author":"Gonzalez","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 1","key":"10.4065\/mcp.2011.0203_bib40","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.trstmh.2006.02.022","article-title":"Treatment of New World cutaneous leishmaniasis with miltefosine","volume":"100","author":"Soto","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-4632.2009.03883.x","article-title":"Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname","volume":"48","author":"van der Meide","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.4065\/mcp.2011.0203_bib42","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa011882","article-title":"Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major","volume":"346","author":"Alrajhi","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0203_bib43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4269\/ajtmh.2007.76.48","article-title":"Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution?","volume":"76","author":"Morizot","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1086\/648726","article-title":"Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan","volume":"50","author":"van Thiel","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib45","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1371\/journal.pntd.0000491","article-title":"First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony","volume":"3","author":"Miranda-Verastegui","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.4065\/mcp.2011.0203_bib46","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/archderm.142.12.1575","article-title":"Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial","volume":"142","author":"Firooz","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.4065\/mcp.2011.0203_bib47","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.4269\/ajtmh.2010.10-0171","article-title":"Liposomal amphotericin B for treatment of cutaneous leishmaniasis","volume":"83","author":"Wortmann","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib48","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1086\/511643","article-title":"Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis","volume":"44","author":"Machado","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib49","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1086\/510588","article-title":"Treatment of Bolivian mucosal leishmaniasis with miltefosine","volume":"44","author":"Soto","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib50","doi-asserted-by":"crossref","first-page":"617521","DOI":"10.1155\/2010\/617521","article-title":"Drug resistance in visceral leishmaniasis","volume":"2010","author":"Maltezou","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.4065\/mcp.2011.0203_bib51","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4269\/ajtmh.2005.73.871","article-title":"A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya","volume":"73","author":"Wasunna","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib52","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/508667","article-title":"The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America","volume":"43","author":"Wormser","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib53","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1056\/NEJM200011163432004","article-title":"Atovaquone and azithromycin for the treatment of babesiosis","volume":"343","author":"Krause","year":"2000","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0203_bib54","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/525852","article-title":"Persistent and relapsing babesiosis in immunocompromised patients","volume":"46","author":"Krause","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/649859","article-title":"Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection","volume":"50","author":"Wormser","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib56","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.ophtha.2005.05.025","article-title":"Prospective randomized trial of trimethoprim\/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis","volume":"112","author":"Soheilian","year":"2005","journal-title":"Ophthalmology"},{"key":"10.4065\/mcp.2011.0203_bib57","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1128\/AAC.42.6.1346","article-title":"Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS","volume":"42","author":"Torre","year":"1998","journal-title":"Antimicrob Agents ChemoTher"},{"key":"10.4065\/mcp.2011.0203_bib58","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1086\/590149","article-title":"Management of Toxoplasma gondii infection during pregnancy","volume":"47","author":"Montoya","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib59","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0140-6736(07)60072-5","article-title":"Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data","volume":"369","author":"Thiebaut","year":"2007","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0203_bib60","first-page":"273","article-title":"The old and new therapeutic approaches to the treatment of giardiasis: where are we?","volume":"3","author":"Busatti","year":"2009","journal-title":"Biologics"},{"key":"10.4065\/mcp.2011.0203_bib61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.exppara.2009.07.005","article-title":"Cryptosporidium and Giardia: treatment options and prospects for new drugs","volume":"124","author":"Rossignol","year":"2010","journal-title":"Exp Parasitol"},{"key":"10.4065\/mcp.2011.0203_bib62","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1371\/journal.pntd.0000682","article-title":"A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis","volume":"4","author":"Solaymani-Mohammadi","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.4065\/mcp.2011.0203_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006085.pub2","article-title":"Antiamoebic drugs for treating amoebic colitis","author":"Gonzales","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.4065\/mcp.2011.0203_bib64","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.trstmh.2007.04.001","article-title":"Nitazoxanide in the treatment of amoebiasis","volume":"101","author":"Rossignol","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib65","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/QCO.0b013e32833de052","article-title":"Treatment of cryptosporidiosis: do we know what we think we know?","volume":"23","author":"Cabada","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004932.pub2","article-title":"Prevention and treatment of cryptosporidiosis in immunocompromised patients","author":"Abubakar","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.4065\/mcp.2011.0203_bib67","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1128\/AAC.00614-09","article-title":"Evaluation of new thiazolide\/thiadiazolide derivatives reveals nitro group-independent efficacy against in vitro development of Cryptosporidium parvum","volume":"54","author":"Gargala","year":"2010","journal-title":"Antimicrob Agents ChemoTher"},{"key":"10.4065\/mcp.2011.0203_bib68","doi-asserted-by":"crossref","first-page":"885","DOI":"10.7326\/0003-4819-132-11-200006060-00006","article-title":"Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients: a randomized, controlled trial","volume":"132","author":"Verdier","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.4065\/mcp.2011.0203_bib69","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1086\/510744","article-title":"Efficacy of nitazoxanide for cyclosporiasis in patients with sulfa allergy","volume":"44","author":"Zimmer","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib70","doi-asserted-by":"crossref","first-page":"474","DOI":"10.7326\/0003-4819-109-6-474","article-title":"Isospora belli infection: treatment with pyrimethamine","volume":"109","author":"Weiss","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.4065\/mcp.2011.0203_bib71","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0035-9203(97)90531-9","article-title":"Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico","volume":"91","author":"Romero Cabello","year":"1997","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib72","doi-asserted-by":"crossref","first-page":"614","DOI":"10.4269\/ajtmh.2010.09-0478","article-title":"A review of the clinical presentation of dientamoebiasis","volume":"82","author":"Stark","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib73","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1542-3565(05)00427-1","article-title":"Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis","volume":"3","author":"Rossignol","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.4065\/mcp.2011.0203_bib74","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2010","volume":"59","author":"Workowski","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.4065\/mcp.2011.0203_bib75","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1128\/AAC.00814-06","article-title":"Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole","volume":"50","author":"Schwebke","year":"2006","journal-title":"Antimicrob Agents ChemoTher"},{"key":"10.4065\/mcp.2011.0203_bib76","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1258\/0956462054308422","article-title":"Management of metronidazole-resistant Trichomonas vaginalis\u2014a new approach","volume":"16","author":"Mammen-Tobin","year":"2005","journal-title":"Int J STD AIDS"},{"key":"10.4065\/mcp.2011.0203_bib77","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1258\/ijsa.2009.009085","article-title":"Paromomycin treatment of recalcitrant Trichomonas vaginalis","volume":"21","author":"Tayal","year":"2010","journal-title":"Int J STD AIDS"},{"key":"10.4065\/mcp.2011.0203_bib78","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drup.2004.01.002","article-title":"Opportunistic amoebae: challenges in prophylaxis and treatment","volume":"7","author":"Schuster","year":"2004","journal-title":"Drug Resist Updat"},{"key":"10.4065\/mcp.2011.0203_bib79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.arcmed.2004.11.003","article-title":"Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous amphotericin B, fluconazole and rifampicin","volume":"36","author":"Vargas-Zepeda","year":"2005","journal-title":"Arch Med Res"},{"key":"10.4065\/mcp.2011.0203_bib80","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s12098-009-0205-z","article-title":"Acanthameba meningitis with successful outcome","volume":"76","author":"Saxena","year":"2009","journal-title":"Indian J Pediatr"},{"key":"10.4065\/mcp.2011.0203_bib81","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3201\/eid1411.070854","article-title":"Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine","volume":"14","author":"Aichelburg","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib82","first-page":"1182","article-title":"Notes from the field: transplant-transmitted Balamuthia mandrillaris\u2014Arizona, 2010","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.4065\/mcp.2011.0203_bib83","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1086\/597260","article-title":"Under the radar: Balamuthia amebic encephalitis","volume":"48","author":"Schuster","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib84","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/379020","article-title":"Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases","volume":"37","author":"Deetz","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib85","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1086\/653609","article-title":"Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement","volume":"51","author":"Martinez","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib86","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijid.2007.04.017","article-title":"Successful treatment of niclosamide- and praziquantel-resistant beef tapeworm infection with nitazoxanide","volume":"12","author":"Lateef","year":"2008","journal-title":"Int J Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib87","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa031294","article-title":"A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis","volume":"350","author":"Garcia","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0203_bib88","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.trstmh.2006.04.004","article-title":"Hymenolepis nana infection: symptoms and response to nitazoxanide in field conditions","volume":"101","author":"Chero","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actatropica.2005.01.013","article-title":"Tribendimidine: a promising, safe and broad-spectrum anthelmintic agent from China","volume":"94","author":"Xiao","year":"2005","journal-title":"Acta Trop"},{"key":"10.4065\/mcp.2011.0203_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actatropica.2009.11.001","article-title":"Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans","volume":"114","author":"Brunetti","year":"2010","journal-title":"Acta Trop"},{"key":"10.4065\/mcp.2011.0203_bib91","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.actatropica.2009.04.006","article-title":"Praziquantel: neglected drug? ineffective treatment? or therapeutic choice in cystic hydatid disease?","volume":"111","author":"Bygott","year":"2009","journal-title":"Acta Trop"},{"key":"10.4065\/mcp.2011.0203_bib92","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0140-6736(06)69440-3","article-title":"Human schistosomiasis","volume":"368","author":"Gryseels","year":"2006","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0203_bib93","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.trstmh.2006.03.003","article-title":"Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks","volume":"101","author":"Boulanger","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib94","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(07)70053-1","article-title":"Katayama syndrome","volume":"7","author":"Ross","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib95","doi-asserted-by":"crossref","first-page":"932","DOI":"10.4269\/ajtmh.1999.60.932","article-title":"Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers","volume":"60","author":"Ismail","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib96","first-page":"190","article-title":"Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial","volume":"81","author":"Ferrari","year":"2003","journal-title":"Bull World Health Organ"},{"key":"10.4065\/mcp.2011.0203_bib97","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0304-4017(00)00267-3","article-title":"Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in The Netherlands","volume":"91","author":"Moll","year":"2000","journal-title":"Vet Parasitol"},{"key":"10.4065\/mcp.2011.0203_bib98","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1365-2036.2003.01419.x","article-title":"Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru","volume":"17","author":"Favennec","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.4065\/mcp.2011.0203_bib99","first-page":"528","article-title":"Studies on the chemotherapy of human opisthorchiasis in Thailand: I. Clinical trial of praziquantel","volume":"11","author":"Bunnag","year":"1980","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.4065\/mcp.2011.0203_bib100","first-page":"27","article-title":"Experimental and clinical trial of albendazole in the treatment of Clonorchiasis sinensis","volume":"104","author":"Liu","year":"1991","journal-title":"Chin Med J (Engl)"},{"key":"10.4065\/mcp.2011.0203_bib101","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1473-3099(10)70250-4","article-title":"Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial","volume":"11","author":"Soukhathammavong","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib102","first-page":"65","article-title":"Clinical field trials of praziquantel in pulmonary paragonimiasis due to Paragonimus uterobilateralis in endemic populations of the Igwun Basin, Nigeria","volume":"40","author":"Udonsi","year":"1989","journal-title":"Trop Med Parasitol"},{"key":"10.4065\/mcp.2011.0203_bib103","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0035-9203(98)90919-1","article-title":"Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy","volume":"92","author":"Calvopina","year":"1998","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib104","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4269\/ajtmh.1970.19.940","article-title":"Treatment of Paragonimus westermani infections with bithionol","volume":"19","author":"Kim","year":"1970","journal-title":"Am J Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib105","first-page":"216","article-title":"Field trial on the treatment of fasciolopsiasis with praziquantel","volume":"14","author":"Bunnag","year":"1983","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.4065\/mcp.2011.0203_bib106","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/jama.299.16.1937","article-title":"Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis","volume":"299","author":"Keiser","year":"2008","journal-title":"JAMA"},{"key":"10.4065\/mcp.2011.0203_bib107","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1086\/657310","article-title":"Albendazole and mebendazole administered alone or in combination with ivermectin against Trichuris trichiura: a randomized controlled trial","volume":"51","author":"Knopp","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib108","first-page":"343","article-title":"Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar","volume":"81","author":"Albonico","year":"2003","journal-title":"Bull World Health Organ"},{"key":"10.4065\/mcp.2011.0203_bib109","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1017\/S0022149X07747466","article-title":"Nitazoxanide in the treatment of Ascaris lumbricoides in a rural zone of Colima, Mexico","volume":"81","author":"Galvan-Ramirez","year":"2007","journal-title":"J Helminthol"},{"key":"10.4065\/mcp.2011.0203_bib110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4269\/ajtmh.2003.68.384","article-title":"Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico","volume":"68","author":"Diaz","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib111","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.actatropica.2008.03.007","article-title":"A randomized, double-blind, multicenter clinical trial on the efficacy of ivermectin against intestinal nematode infections in China","volume":"106","author":"Wen","year":"2008","journal-title":"Acta Trop"},{"key":"10.4065\/mcp.2011.0203_bib112","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/archpedi.1969.02100040578007","article-title":"Reinfection in enterobiasis (pinworm infection). Simultaneous treatment of family members","volume":"118","author":"Matsen","year":"1969","journal-title":"Am J Dis Child"},{"key":"10.4065\/mcp.2011.0203_bib113","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1517\/14656566.5.12.2615","article-title":"Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis","volume":"5","author":"Igual-Adell","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.4065\/mcp.2011.0203_bib114","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4269\/ajtmh.1996.55.477","article-title":"A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children","volume":"55","author":"Marti","year":"1996","journal-title":"Am J Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib115","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/CMR.17.1.208-217.2004","article-title":"Strongyloides stercoralis in the immunocompromised population","volume":"17","author":"Keiser","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"10.4065\/mcp.2011.0203_bib116","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4269\/ajtmh.2005.73.911","article-title":"Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis","volume":"73","author":"Turner","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib117","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1086\/430827","article-title":"Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin","volume":"41","author":"Marty","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib118","first-page":"531","article-title":"Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis","volume":"35","author":"Pornsuriyasak","year":"2004","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.4065\/mcp.2011.0203_bib119","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1086\/315645","article-title":"Blinded, placebo-controlled trial of antiparasitic drugs for trichinosis myositis","volume":"182","author":"Watt","year":"2000","journal-title":"J Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/00034983.1989.11812374","article-title":"Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial","volume":"83","author":"Sturchler","year":"1989","journal-title":"Ann Trop Med Parasitol"},{"issue":"pt 5","key":"10.4065\/mcp.2011.0203_bib121","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1017\/S0031182000065240","article-title":"Comparative efficacy of diethylcarbamazine and mebendazole for the treatment of human toxocariasis","volume":"110","author":"Magnaval","year":"1995","journal-title":"Parasitology"},{"key":"10.4065\/mcp.2011.0203_bib122","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/108076801750295317","article-title":"Treatment of ocular toxocariasis with albendazole","volume":"17","author":"Barisani-Asenbauer","year":"2001","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.4065\/mcp.2011.0203_bib123","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.4065\/mcp.2011.0203_bib124","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/QCO.0b013e328315cde7","article-title":"Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis","volume":"21","author":"Hoerauf","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/509325","article-title":"Recent updates on onchocerciasis: diagnosis and treatment","volume":"44","author":"Udall","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib126","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(10)60586-7","article-title":"Lymphatic filariasis and onchocerciasis","volume":"376","author":"Taylor","year":"2010","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0203_bib127","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.trstmh.2008.03.022","article-title":"Loiasis: African eye worm","volume":"102","author":"Padgett","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.4065\/mcp.2011.0203_bib128","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/infdis\/168.1.202","article-title":"Albendazole in human loiasis: results of a double-blind, placebo-controlled trial","volume":"168","author":"Klion","year":"1993","journal-title":"J Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib129","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-4362.2001.01103.x","article-title":"Treatment of larva migrans cutanea (creeping eruption): a comparison between albendazole and traditional therapy","volume":"40","author":"Albanese","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.4065\/mcp.2011.0203_bib130","first-page":"172","article-title":"Treatment of eosinophilic meningitis with a combination of albendazole and corticosteroid","volume":"35","author":"Chotmongkol","year":"2004","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.4065\/mcp.2011.0203_bib131","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3201\/eid1306.061541","article-title":"Full recovery from Baylisascaris procyonis eosinophilic meningitis","volume":"13","author":"Pai","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.4065\/mcp.2011.0203_bib132","first-page":"374","article-title":"Comparison of ivermectin and albendazole treatment for gnathostomiasis","volume":"31","author":"Nontasut","year":"2000","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.4065\/mcp.2011.0203_bib133","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1128\/CMR.5.2.120","article-title":"Intestinal capillariasis","volume":"5","author":"Cross","year":"1992","journal-title":"Clin Microbiol Rev"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611600554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611600554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T09:37:31Z","timestamp":1706002651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611600554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":132,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0025619611600554"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2011.0203","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiparasitic Therapy","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2011.0203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}